spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Onyx Pharmaceuticals 

 HSMN NewsFeed - 7 Sep 2023
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Aug 2022
3T Biosciences Debuts with $40 Million Series A Financing
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jul 2021
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2019
Mirum Pharmaceuticals Appoints Chris Peetz as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2018
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2017
Mitra Appoints Anton Ehrhardt as Vice President of Medical Affairs
Diagnostics Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Jan 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2015
Lori Kunkel, M.D., Joins Tocagen's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Jul 2015
Xencor Appoints Yujiro S. Hata to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Apr 2015
Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Aug 2014
Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
Biopharmaceuticals Dermatology Venture Capital Personnel
 HSMN NewsFeed - 14 Aug 2014
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jun 2014
ARIAD Announces Three Key Appointments to Its Global Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2014
Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2014
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2014
Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2014
Atara Biotherapeutics Strengthens Board and Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2014
William R. Ringo Joins Mirati Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2014
Immune Design Appoints William Ringo to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2014
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2013
Lorus Therapeutics Completes New Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2013
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Sep 2013
Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 31 May 2013
Plexxikon Announces Program Update and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Mar 2013
Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer
Regenerative Medicine Cardiology Personnel
 HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2012
Nodality, Inc. Appoints Laura Brege as Chief Executive Officer
Personalized Medicine Personnel
 HSMN NewsFeed - 14 Aug 2012
Pharmacyclics(R) Appoints Joshua T. Brumm Executive Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2012
Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2012
Delcath Announced Changes To Board Of Directors
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 4 Jun 2012
Phase 3 Data on Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2012
Phase III Data on Bayer's Regorafenib Met Primary Endpoint Showing Significant Improvement in Progression-Free Survival in Patients with GIST
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2012
Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Feb 2012
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2011
Phase III Trial of Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Aug 2011
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2011
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive Officer
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 28 Feb 2011
ZELTIQ(TM) Starts 2011 by Strengthening Management Team
Devices Personnel
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2011
Cytokinetics Announces Changes to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2011
3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2011
Ligand Acquires CyDex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Jan 2011
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jan 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2010
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2010
Eddingpharm (Cayman) Inc. Announces Closing of Series B Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2010
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2010
Calithera Biosciences Closes $40 Million in Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 May 2010
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2010
Nuon Therapeutics Names Lee Rauch Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2010
Silence Therapeutics Appoints Max Herrmann as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Apr 2010
Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Mar 2010
Portola Pharmaceuticals Announces Senior Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Feb 2010
TOPICA Names Mark W. Davis Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2009
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2009
Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2008
NPS Pharmaceuticals Announces Senior Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Feb 2008
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2008
Two New Independent Directors Join Chelsea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2008
Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2008
Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2007
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2007
Onyx Pharmaceuticals Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
BioVex Appoints Dr. Leonard Post to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Hepatobiliary Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Aug 2007
Angiotech appoints Laura Brege to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2007
Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Ambit Biosciences Appoints Wendell Wierenga, Ph.D., as Executive Vice President of Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2006
Anesiva Bolsters Executive Team With Two Vice President Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jun 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jun 2006
Onyx Names Laura A. Brege Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2006
Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2006
Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2006
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2006
European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Mar 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Feb 2006
Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets in Combination With Two Chemotherapeutic Agents
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 39

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 39 additional stories matching:
Onyx Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.